AQR Capital Management
YMAB

AQR Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

AQR Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-252,142
Closed -$1.14M – 3612
2025
Q2 		$1.14M Buy
252,142
+87,354
+53% +$393K ﹤0.01% 2122
2025
Q1 		$730K Buy
164,788
+147,788
+869% +$858K ﹤0.01% 2214
2024
Q4 		$133K Sell
17,000
-10,247
-38% -$125K ﹤0.01% 2734
2024
Q3 		$358K Buy
27,247
+5,321
+24% +$67.5K ﹤0.01% 2314
2024
Q2 		$265K Sell
21,926
-15,915
-42% -$215K ﹤0.01% 2321
2024
Q1 		$615K Buy
+37,841
New +$510K ﹤0.01% 1881
2023
Q4 		– Sell
-245,482
Closed -$1.34M – 2459
2023
Q3 		$1.34M Buy
245,482
+45,982
+23% +$268K ﹤0.01% 1490
2023
Q2 		$1.35M Sell
199,500
-279,793
-58% -$2.1M ﹤0.01% 1433
2023
Q1 		$2.4M Sell
479,293
-877
-0.2% -$3.58K 0.01% 1174
2022
Q4 		$2.34M Buy
+480,170
New +$3.49M 0.01% 1194

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AQR Capital Management's YMAB Position: Q3 2025 in Review

AQR Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 252,142 shares — an estimated $1.14M sold.

AQR Capital Management first reported a position in YMAB in Q4 2022 and held it in 10 quarters. The position peaked at $2.4M in Q1 2023. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • AQR Capital Management reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 252,142 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.14M.
  • AQR Capital Management first reported a position in Y-mAbs Therapeutics in Q4 2022 and held it in 10 quarters.
  • AQR Capital Management's Y-mAbs Therapeutics position peaked at $2.4M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.